AstraZeneca China R&D Day: Reshaping Patient Trajectories in Chronic and Rare Diseases

On October 19, 2023, the "AstraZeneca China R&D Day – Reshaping the Patient Journey" event, focusing on chronic diseases and rare disease fields, will be grandly launched. The four-day AstraZeneca China R&D Day event is unprecedented in scale, featuring one main forum and ten sub-forums. More than forty scientists, scholars, and expert speakers from China's top universities, clinical research centers, and biotech innovation companies, as well as nearly twenty top scientists from various disease areas of AstraZeneca’s global R&D team, will engage in close scientific discussions with on-site participants.

Under the full support of Sharon Barr, Executive Vice President of AstraZeneca and Head of Biopharmaceuticals R&D, and Gianluca Pirozzi, Senior Vice President of AstraZeneca and Head of Rare Disease Clinical Development, global R&D leaders across different disease areas of AstraZeneca, business development leaders, and heads of R&D in various disease areas in China will participate in this R&D Day event. Academic exchanges and discussions will be held with speakers and attendees on amyloid cardiomyopathy, rare kidney diseases, rare neurological diseases, cardiovascular diseases, non-alcoholic steatohepatitis, respiratory diseases, autoimmune diseases, and vaccine development to explore further collaboration opportunities and help China’s innovation become a global driving force in pharmaceutical R&D. The hot topics of this event include: